Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies

Michael Harvey Rivner, Mamatha Pasnoor, Mazen M. Dimachkie, Richard J. Barohn, Lin Mei

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

Original languageEnglish (US)
Pages (from-to)293-310
Number of pages18
JournalNeurologic Clinics
Volume36
Issue number2
DOIs
StatePublished - May 1 2018

Fingerprint

Myasthenia Gravis
Protein-Tyrosine Kinases
Muscles
Antibodies
Cholinergic Receptors
LDL-Receptor Related Proteins
LDL Receptors
Cholinesterase Inhibitors
Immunosuppressive Agents
Head
Phenotype

Keywords

  • Agrin
  • Cortactin
  • LRP4
  • MuSK
  • Myasthenia gravis
  • Rapsyn

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. / Rivner, Michael Harvey; Pasnoor, Mamatha; Dimachkie, Mazen M.; Barohn, Richard J.; Mei, Lin.

In: Neurologic Clinics, Vol. 36, No. 2, 01.05.2018, p. 293-310.

Research output: Contribution to journalReview article

Rivner, Michael Harvey ; Pasnoor, Mamatha ; Dimachkie, Mazen M. ; Barohn, Richard J. ; Mei, Lin. / Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies. In: Neurologic Clinics. 2018 ; Vol. 36, No. 2. pp. 293-310.
@article{380d3ee4f9e74b6d873d470771968667,
title = "Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies",
abstract = "Around 20{\%} of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30{\%} to 40{\%} of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.",
keywords = "Agrin, Cortactin, LRP4, MuSK, Myasthenia gravis, Rapsyn",
author = "Rivner, {Michael Harvey} and Mamatha Pasnoor and Dimachkie, {Mazen M.} and Barohn, {Richard J.} and Lin Mei",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.ncl.2018.01.004",
language = "English (US)",
volume = "36",
pages = "293--310",
journal = "Neurologic Clinics",
issn = "0733-8619",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Muscle-Specific Tyrosine Kinase and Myasthenia Gravis Owing to Other Antibodies

AU - Rivner, Michael Harvey

AU - Pasnoor, Mamatha

AU - Dimachkie, Mazen M.

AU - Barohn, Richard J.

AU - Mei, Lin

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

AB - Around 20% of patients with myasthenia gravis are acetylcholine receptor antibody negative; muscle-specific tyrosine kinase antibodies (MuSK) were identified as the cause of myasthenia gravis in 30% to 40% of these cases. Anti MuSK myasthenia gravis is associated with specific clinical phenotypes. One is a bulbar form with fewer ocular symptoms. Others show an isolated head drop or symptoms indistinguishable from acetylcholine receptor-positive myasthenia gravis. These patients usually respond well to immunosuppressive therapy, but not as well to cholinesterase inhibitors. Other antibodies associated with myasthenia gravis, including low-density lipoprotein receptor-related protein 4, are discussed.

KW - Agrin

KW - Cortactin

KW - LRP4

KW - MuSK

KW - Myasthenia gravis

KW - Rapsyn

UR - http://www.scopus.com/inward/record.url?scp=85045219550&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045219550&partnerID=8YFLogxK

U2 - 10.1016/j.ncl.2018.01.004

DO - 10.1016/j.ncl.2018.01.004

M3 - Review article

C2 - 29655451

AN - SCOPUS:85045219550

VL - 36

SP - 293

EP - 310

JO - Neurologic Clinics

JF - Neurologic Clinics

SN - 0733-8619

IS - 2

ER -